Advertisement

Relation of Hepatic Steatosis to Atherogenic Dyslipidemia

Published:September 09, 2013DOI:https://doi.org/10.1016/j.amjcard.2013.08.001
      Hepatic steatosis is closely associated with the metabolic syndrome. We assessed for an independent association between hepatic steatosis and atherogenic dyslipidemia after adjustment for obesity, physical activity, hyperglycemia, and systemic inflammation. We studied 6,333 asymptomatic subjects without clinical cardiovascular disease undergoing a health screen in Brazil from November 2008 to July 2010. Hepatic steatosis was diagnosed by ultrasound. Atherogenic dyslipidemia was defined using 2 definitions: criteria for (1) metabolic syndrome or (2) insulin resistance (triglyceride/high-density–lipoprotein cholesterol ratio of ≥2.5 in women and ≥3.5 in men). In hierarchical multivariate regression models, we evaluated for an independent association of hepatic steatosis with atherogenic dyslipidemia. Hepatic steatosis was detected in 36% of participants (average age 43.5 years, 79% men, average body mass index 26.3 kg/m2). Subjects with hepatic steatosis had similar levels of low-density–lipoprotein cholesterol, with significantly lower level of high-density–lipoprotein cholesterol and higher level of triglyceride compared with those without steatosis. Hepatic steatosis remained significantly independently associated with atherogenic dyslipidemia of both definitions (metabolic syndrome [odds ratio 2.47, 95% confidence interval 2.03 to 3.02] and insulin resistance [odds ratio 2.50, 95% confidence interval 2.13 to 2.91]) after multivariate adjustment. Stratified analyses showed a persistent independent association in nonobese subjects, those without metabolic syndrome, those with normal high-sensitivity C-reactive protein, nonalcohol abusers, and those with normal liver enzymes. Hepatic steatosis was significantly associated with atherogenic dyslipidemia independent of obesity, physical activity, hyperglycemia, and systemic inflammation after multivariate adjustment. In conclusion, this adds to the growing body of evidence that hepatic steatosis may play a direct metabolic role in conferring increased cardiovascular risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adiels M.
        • Taskinen M.
        • Packard C.
        • Caslake M.
        • Soro-Paavonen A.
        • Westerbacka J.
        • Vehkavaara S.
        • Häkkinen A.
        • Olofsson S.
        • Yki-Järvinen H.
        • Borén J.
        Overproduction of large VLDL particles is driven by increased liver fat content in man.
        Diabetologia. 2006; 49: 755-765
        • Blake G.J.
        • Otvos J.D.
        • Rifai N.
        • Ridker P.M.
        Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.
        Circulation. 2002; 106: 1930-1937
        • Berneis K.K.
        • Krauss R.M.
        Metabolic origins and clinical significance of LDL heterogeneity.
        J Lipid Res. 2002; 43: 1363-1379
        • Cromwell W.C.
        • Otvos J.D.
        Low-density lipoprotein particle number and risk for cardiovascular disease.
        Curr Atheroscler Rep. 2004; 6: 381-387
        • Gardner C.D.
        • Fortmann S.P.
        • Krauss R.M.
        Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.
        J Am Med Assoc. 1996; 276: 875-881
        • Blaha M.
        • Blumenthal R.
        • Brinton E.
        • Jacobson T.
        The importance of non-HDL cholesterol reporting in lipid management.
        J Clin Lipidol. 2008; 2: 267-273
        • Perloff D.
        • Grim C.
        • Flack J.
        • Frohlich E.D.
        • Hill M.
        • McDonald M.
        • Morgenstern B.Z.
        Human blood pressure determination by sphygmomanometry.
        Circulation. 1993; 88: 2460-2470
        • Bush K.
        • Kivlahan D.R.
        • McDonell M.B.
        • Fihn S.D.
        • Bradley K.A.
        The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test.
        Arch Intern Med. 1998; 158: 1789-1795
        • Craig C.L.
        • Marshall A.L.
        • Sjöström M.
        • Bauman A.E.
        • Booth M.L.
        • Ainsworth B.E.
        • Pratt M.
        • Ekelund U.
        • Yngve A.
        • Sallis J.F.
        • Oja P.
        International physical activity questionnaire: 12-country reliability and validity.
        Med Sci Sports Exerc. 2003; 35: 1381-1395
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Joseph A.E.
        • Saverymuttu S.H.
        • al-Sam S.
        • Cook M.G.
        • Maxwell J.D.
        Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease.
        Clin Radiol. 1991; 43: 26-31
        • Saadeh S.
        • Younossi Z.M.
        • Remer E.M.
        • Gramlich T.
        • Ong J.P.
        • Hurley M.
        • Mullen K.D.
        • Cooper J.N.
        • Sheridan M.J.
        The utility of radiological imaging in nonalcoholic fatty liver disease.
        Gastroenterology. 2002; 123: 745-750
        • Alberti K.G.
        • Eckel R.H.
        • Grundy S.M.
        • Zimmet P.Z.
        • Cleeman J.I.
        • Donato K.A.
        • Fruchart J.C.
        • James W.P.
        • Loria C.M.
        • Smith Jr., S.C.
        Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
        Circulation. 2009; 120: 1640-1645
        • Salazar M.R.
        • Carbajal H.A.
        • Espeche W.G.
        • Leiva Sisnieguez C.E.
        • Balbín E.
        • Dulbecco C.A.
        • Aizpurúa M.
        • Marillet A.G.
        • Reaven G.M.
        Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women.
        Am J Cardiol. 2012; 109: 1749-1753
        • Kotronen A.
        • Yki-Jarvinen H.
        Fatty liver: a novel component of the metabolic syndrome.
        Arterioscler Thromb Vase Biol. 2008; 28: 27-38
        • Ndumele C.E.
        • Nasir K.
        • Conceiçao R.D.
        • Carvalho J.A.
        • Blumenthal R.S.
        • Santos R.D.
        Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation.
        Arterioscler Thromb Vasc Biol. 2011; 31: 1927-1932
        • Targher G.
        • Bertolini L.
        • Poli F.
        • Rodella S.
        • Scala L.
        • Tessari R.
        • Zenari L.
        • Falezza G.
        Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
        Diabetes. 2005; 54: 3541-3546
        • Toledo F.G.S.
        • Sniderman A.D.
        • Kelley D.E.
        Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.
        Diabetes Care. 2006; 29: 1845-1850
        • Chan D.
        • Watts G.
        • Gan S.
        • Wong A.
        • Ooi E.
        • Barrett H.
        Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoportein-apolipoprotein B-100 in obesity.
        Arterioscler Thromb Vasc Biol. 2010; 30: 1043-1050
        • Adiels M.
        • Taskinen M.R.
        • Boren J.
        Fatty liver, insulin resistance, and dyslipidemia.
        Curr Diab Rep. 2008; 8: 60-64
        • Zambon A.
        • Hokanson J.E.
        • Brown B.G.
        • Brunzell J.D.
        Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
        Circulation. 1999; 99: 1959-1964
        • Rashid S.
        • Watanabe T.
        • Sakaue T.
        • Lewis G.F.
        Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity.
        Clin Biochem. 2003; 36: 421-429
        • Sniderman A.
        • Couture P.
        • de Graaf J.
        Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
        Nat Rev Endocrinol. 2010; 6: 335-346
        • Browning J.D.
        • Horton J.D.
        Molecular mediators of hepatic steatosis and liver injury.
        J Clin Invest. 2004; 114: 147-152
        • Hosoyamada K.
        • Uto H.
        • Imamura Y.
        • Hiramine Y.
        • Toyokura E.
        • Hidaka Y.
        • Kuwahara T.
        • Kusano K.
        • Saito K.
        • Oketani M.
        • Ido A.
        • Tsubouchi H.
        Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol.
        Diabetol Metab Syndr. 2012; 4: 34
        • DeFilippis A.P.
        • Blaha M.J.
        • Martin S.S.
        • Reed R.M.
        • Jones S.R.
        • Nasir K.
        • Blumenthal R.S.
        • Budoff M.J.
        Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.
        Atherosclerosis. 2013; 227: 429-436